Molecule News and Research

RSS

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

Bruker launches new, improved customer-driven products at Pittcon 2014

At Pittcon 2014, Bruker today announced new product introductions and enhancements for improved performance and customer experience in research, industrial and applied markets.

4 Mar 2014

Blocking Netrin-1 in immune system stops chronic inflammation and insulin resistance tied to obesity

Researchers at NYU Langone Medical Center have found that blocking the action of a key signaling molecule in the immune system known as Netrin-1 stalls chronic inflammation and insulin resistance tied to obesity and often derived from fatty diets.

4 Mar 2014

Drug that blocks LTA4 hydrolase enzyme plays key role in body's inflammatory response

There have been great expectations regarding the production of a drug to block the enzyme LTA4 hydrolase, which plays a key role in the body's inflammatory response.

4 Mar 2014

Levels of bisphenol A in men's urine could be marker of prostate cancer

Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.

4 Mar 2014

New molecule fluorogenic probe for rapid assessment of individual's risk for Parkinson's disease

A team of researchers from National University of Singapore (NUS) have created the first two-photon, small molecule fluorogenic probe that can serve as a useful tool for the rapid assessment of an individual's potential risk for Parkinson's disease.

3 Mar 2014

RainDance Technologies closes $16.5 million Series E financing round

RainDance Technologies, Inc., an innovative genomics tools company making molecular testing of complex diseases more standardized and readily available, today announced that it has closed a $16.5 million Series E financing round extension. New investors include GE Ventures and Northgate Capital; all existing financial investors also participated in this round of financing.

3 Mar 2014

Microencapsulated drug delivery may soon revolutionize cancer treatment

Invasive and systemic cancer treatment is a necessary evil for many people with the devastating diagnosis. These patients endure therapies with ravaging side effects, including nausea, immune suppression, hair loss and even organ failure, in hopes of eradicating cancerous tissues in the body.

3 Mar 2014

Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds developed by scientists of Ludwig-Maximilians-Universitaet (LMU) in Munich directly modulate nerve-cell function, and open new routes to the treatment of neurological diseases, including chronic pain and certain types of visual impairment.

3 Mar 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

3D structure of enzyme helps defend against bacteria

An essential weapon in the body's fight against infection has come into sharper view. Researchers at Princeton University have discovered the 3D structure of an enzyme that cuts to ribbons the genetic material of viruses and helps defend against bacteria.

3 Mar 2014

UCLA develops experimental treatment that eliminates acute type of leukemia in mice

A diverse team of scientists from UCLA's Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects.

28 Feb 2014

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus.

28 Feb 2014

Study identifies promising target for new drugs to treat lethal form of brain cancer

A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

27 Feb 2014

Scientists reveal two regulatory mechanisms that keep the body's immune response in check

A Keck Medicine of USC-led team of microbiologists has identified previously unknown interactions between critical proteins in the human immune response system, uncovering two independent regulatory mechanisms that keep the body's immune response in check. Their findings appear in the February 2014 edition of Cell Host & Microbe, the top peer-reviewed scientific journal that focuses on the study of cell-pathogen interaction.

27 Feb 2014

Cedars-Sinai researchers develop unique imaging device to "light up" malignant brain tumors

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery have developed a unique, compact, relatively inexpensive imaging device to "light up" malignant brain tumors and other cancers.

27 Feb 2014

Study shows fructose consumption does not contribute to non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease is the most common chronic liver disease in developed countries, affecting up to 30 per cent of their populations.

27 Feb 2014

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M is a cell surface protein from Mycoplasma Genitalium that binds to all human antibodies.

26 Feb 2014

Researchers produce extremely accurate and detailed images of "toxic injections"

Bacteria have developed many different ways of smuggling their toxic cargo into cells. Tripartite Tc toxin complexes, which are used by bacteria like the plague pathogen Yersinia pestis and the insect pathogen Photorhabdus luminescens, are particularly unusual.

25 Feb 2014

Research could lead to early diagnosis and treatment of prostate cancer

Prostate cancer patients could get better diagnosis and treatment for the disease in the future thanks to a successful research project at the University of Essex.

25 Feb 2014

Molecule News and Research

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Bruker launches new, improved customer-driven products at Pittcon 2014

Blocking Netrin-1 in immune system stops chronic inflammation and insulin resistance tied to obesity

Drug that blocks LTA4 hydrolase enzyme plays key role in body's inflammatory response

Levels of bisphenol A in men's urine could be marker of prostate cancer

New molecule fluorogenic probe for rapid assessment of individual's risk for Parkinson's disease

RainDance Technologies closes $16.5 million Series E financing round

Microencapsulated drug delivery may soon revolutionize cancer treatment

Photoreactive compounds open new routes to treatment of neurological diseases

Scientists map key elements of immune overreaction triggered by influenza virus infection

3D structure of enzyme helps defend against bacteria

UCLA develops experimental treatment that eliminates acute type of leukemia in mice

TSRI scientists describe severe immune overreaction caused by flu infections

Study identifies promising target for new drugs to treat lethal form of brain cancer

Scientists reveal two regulatory mechanisms that keep the body's immune response in check

Cedars-Sinai researchers develop unique imaging device to "light up" malignant brain tumors

Study shows fructose consumption does not contribute to non-alcoholic fatty liver disease

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Researchers produce extremely accurate and detailed images of "toxic injections"

Research could lead to early diagnosis and treatment of prostate cancer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News